Advertisement

MMRF Launches CureCloud to Advance Precision Medicine


Advertisement
Get Permission

The Multiple Myeloma Research Foundation (MMRF) announced recently that it is launching the MMRF CureCloud, a centralized data hub that generates, aggregates, and visualizes data to accelerate the delivery of precision medicine to patients with multiple myeloma. The CureCloud is a critical part of the organization’s bold 3-year plan, which is to transform patient care through addressing the medical industry’s biggest challenge: data sharing and collection.

The MMRF is working with Broad Genomics, Broad Data Science Platform, COTA, Inc., Tempus, EMSI Health, Prometheus Research, LLC, and PierianDx to address a fundamental, and complex, challenge in health care that is often overlooked—the need for shared, comprehensive data to identify targets and inform data-driven treatment decisions for patients with multiple myeloma. Given that multiple myeloma is a highly heterogenous disease, substantial amounts of genomic, immune, and clinical data need to be curated and shared across physicians, researchers, and patients to drive more effective treatments.

The CureCloud model will include the MMRF’s landmark CoMMpassSM study, the largest genomic data set in any cancer, which identified 12 unique subtypes within myeloma, as well as other MMRF legacy assets and external data sources. Patient data will be de-identified and securely stored.

The MMRF will provide access to these data to every stakeholder in the multiple myeloma ecosystem. A suite of analytics and visualization tools will enable patients and their doctors to compare clinical and genomic data with patients in the CureCloud to help inform treatment decisions as well as to assist researchers to identify new targets and generate hypotheses.

Later this fall, the MMRF will launch a patient registry in which patients will be invited to contribute their clinical and genomic, and eventually immune, data to the CureCloud. These data will provide further insights and help inform data-driven decisions. This research initiative is currently being piloted with a limited number of patients. 


Advertisement

Advertisement



Advertisement